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Introduction:
Stimulant abuse is a rapidly growing epidemic both in the United States, and around the
world. Reports show that nearly 4.7 million Americans have tried methamphetamines at
least once. It is known that methamphetamines and related compounds significantly
increase cardiovascular morbidity and mortality. Substance-related chronic
inflammation and tissue fibrosis can cause irreversible cardiac structural changes, leading
to conditions like methamphetamine-associated dilated cardiomyopathy (MACM). Left
ventricular dilation results in hemodynamic flow disturbances, which promote turbulent
blood flow and stagnation. Furthermore, the sympathomimetic effects of
methamphetamines also disrupt pathways in coagulation homeostasis, providing further
incitement of thrombus formation. This unstable catecholamine driven pathway is thought to 
create myocardial ischemia via direct free radical oxidation, mitochondrial injury, and metabolic
derangements. This is thought to be the cause of left ventricular systolic dysfunction with apical
ballooning and hypokinesis. Here, we report a case of large left ventricular thrombus formation 
in the setting of methamphetamine-associated cardiomyopathy.
Case Report:
Substance-related chronic inflammation and tissue fibrosis can cause irreversible cardiac
structural changes, leading to conditions like methamphetamine associated dilated 
cardiomyopathy (MACM). Left ventricular dilation results in hemodynamic flow disturbances
which promote turbulent blood flow and stagnation. Furthermore, the sympathomimetic effects
of methamphetamines also disrupt pathways in coagulation homeostasis, providing further
incitement of thrombus formation. Here, we report a case of large, left ventricular thrombus
formation in the setting of methamphetamine associated cardiomyopathy and unfortunately
resulted in flash pulmonary edema and acute systolic congestive heart failure with cardiogenic
shock. A contrast CT scan of the chest revealed extensive bilateral pleural effusions and 
atelectasis. A 2.4 cm opacity was seen in the apex of the left ventricle suggesting the presence 
of a thrombus (Figure 1).  Transthoracic echocardiogram identified an echogenic mass
measuring  2.1×1.8×1.8 cm (Figure 2).
Conclusion:
Considering that amphetamine-containing products are listed by national reports as one
of the most widely abused illicit substances, clinicians must be aware of the many
complications associated with their use. Pertinent to the case presented, MACM is
not an uncommon cardiac complication within this patient population. Methamphetamines play a 
significant causative role in numerous cardiac pathologies, including hypertension,
tachyarrhythmias, coronary vasospasm, and cardiomyopathies. Abuse of centrally acting 
stimulants results in a state of sympathetic overdrive due to excessive catecholamine 
production. This response leads to uncontrolled hypertension, tachycardia, and stress induced 
cardiomyopathy (Takotsubo). Some cases have been reported of myocardial infarction without
evidence of epicardial coronary stenosis, suggesting global coronary microvascular
vasospasm and a diagnosis of myocardial infarction with non-obstructed coronary arteries
(MINOCA). There are reports that suggest that the myocardial structural changes can be
 
 
reversible with cessation of methamphetamine use. Unfortunately, with persistent or prolonged 
use, these changes become irreversible, leading to ventricular dilation and fibrosis.  
We have reviewed some of the potential cardiac complications of methamphetamine 
use, focusing on catecholamine-driven methamphetamine-associated dilated 
cardiomyopathy with associated thrombus formation. Currently, there are no guideline driven 
recommendations for methamphetamine user screening with 2D-TTE or for 
prophylactic anticoagulation for patients with dilated cardiomyopathy. Although this is 
the case, we would like to urge clinicians to become familiar with these potential 
complications and screen select patients with symptoms or who are at higher risk for 
complications. We would also like to emphasize the importance of obtaining a detailed 
social history and providing patient education on potential complications. 
 
Figure 1: Contrast CT scan of the chest 
A 2.4 cm opacity can be seen within the apex of the left ventricle (LV) consistent with thrombus 






Figure 2: 2d-Transthoracic Echocardiography: A left ventricular apical thrombus can be seen 
on 2d-TTE in the 4-chamber apical view.
